The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 82, Issue 2, 2008, Pages 214-218

  Erdem, Gokhan ^a   Dogru, Teoman ^a   Tasci, Ilker ^a   Bozoglu, Ergun ^a   Muhsiroglu, Ozlem ^a   Tapan, Serkan ^a   Ercin, Cemal Nuri ^a   Sonmez, Alper ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Metformin; Pioglitazone; Type 2 diabetes; Visfatin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; VISFATIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE INCREASE; FAT NECROSIS; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; THIAZOLIDINEDIONES; WAIST CIRCUMFERENCE;

EID: 54549108811     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.07.021     Document Type: Article

References (35)

1. Stears A.J., and Byrne C.D. Adipocyte metabolism and the metabolic syndrome. Diabetes Obes. Metab. 3 (2001) 129-142
2. Fukuhara, Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
3. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91 (2006) 295-299
4. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res. Clin. Pract. 76 (2007) 24-29
5. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med. Sci. Monit. 12 (2006) 112-119
6. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
7. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: an update. Ann. Intern. Med. 137 (2002) 25-33
8. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
9. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., and Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56 (2007) 451-458
10. Hsieh C.H., He C.T., Lee C.H., Wu L.Y., and Hung Y.J. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism 56 (2007) 1087-1092
11. Riera-Guardia N., and Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes. Metab. 10 (2008) 367-375
12. Kim H.J., Kang E.S., Kim D.J., Kim S.H., Ahn C.W., Cha B.S., et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin. Endocrinol. 66 (2007) 282-289
13. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
14. Samara A., Pfister M., Marie B., and Visvikis-Siest S. Visfatin, low-grade inflammation and BMI. Clin. Endocrinol. 69 (2008) 568-574
15. Jin H., Jiang B., Tang J., Lu W., Wang W., Zhou L., et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res. Clin. Pract. 79 (2008) 412-418
16. Oki K., Yamane K., Kamei N., Nojima H., and Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin. Endocrinol. (Oxf.) 67 (2007) 796-800
17. Wang P., van Greevenbroek M.M., Bouwman F.G., Brouwers M.C., van der Kallen C.J., Smit E., et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflug. Arch. 454 (2007) 971-976
18. Ingelsson E., Larson M.G., Fox C.S., Yin X., Wang T.J., Lipinska I., et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 30 (2007) 1278-1280
19. Sethi J.K., and Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol. Med. 11 (2005) 344-347
20. R. Retnakaran, B.S. Youn, Y. Liu, A.J. Hanley, N.S. Lee, J.W. Park, et al., Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin. Endocrinol. (Oxf.) 10 (in press), doi:10.1111/j.1365-2265.2008.03264.x.
21. Choi K.C., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem. Biophys. Res. Commun. 336 (2005) 747-753
22. Ando H., Yanagihara H., Hayashi Y., Obi Y., Tsuruoka S., Takamura T., et al. Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue. Endocrinology 145 (2005) 5631-5636
23. Hammarstedt A., Pihlajamäki J., Sopasakis V.R., Gogg S., Jansson P.A., Laakso M., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J. Clin. Endocrinol. Metab. 91 (2006) 1181-1184
24. De Jager J., Kooy A., Lehert P., Bets D., Wulffele M.G., Teerlink T., et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 257 (2005) 100-109
25. Kalan M.J., Fogle R.H., Baker M.B., Allen R.B., Sokol R.J., and Stanczyk F.Z. The effect of metformin on serum visfatin in relation to polycystic ovarian syndrome, obesity and insulin resistance. Fertil. Steril. 88 (2007) S78
26. Ibanez L., Lopez-Bermejo A., Diaz M., Enriquez G., Valls C., and de Zegher F. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin. Endocrinol. 68 (2008) 317-320
27. Pfützner A., Hanefeld M., Lübben G., Weber M.M., Karagiannis E., Köhler C., et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk: results from the PIOSTAT study. Horm. Metab. Res. 39 (2007) 764-768
28. Szmitko P.E., Teoh H., Stewart D.J., and Verma S. Adiponectin and cardiovascular disease: state of the art?. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) 1655-1663
29. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 14 (2003) 561-566
30. Sharma P.K., Bhansali A., Sialy R., Malhotra S., and Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 65 (2006) 722-728
31. Erdem G., Dogru T., Tasci I., Sonmez A., and Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116 (2008) 289-292
32. Phillips S.A., Ciaraldi T.P., Kong A.P., Bandukwala R., Aroda V., Carter L., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52 (2003) 667-674
33. Tiikkainen M., Häkkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
34. Kadoglou N.P., Iliadis F., Angelopoulou N., Perrea D., Liapis C.D., and Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Diabet. Med. 25 (2008) 333-340
35. Ikeda Y., Osaki F., Maruyama H., Inada S., Shinahara M., Inoue K., et al. The effect of pioglitazone on circulating adiponectin is highly predictable based on its basal level. Diabetes Res. Clin. Pract. 80 (2008) 12-13